This study compared the ability of three N methyl-D-aspartate (NMDA) receptor antagonists to pre vent neuronal degeneration in an animal model of global cerebral ischemia. The model employed is characterized by damage to the striatum, hippocampus, and neocortex. Antagonists were administered to gerbils either before or after a 5-min bilateral carotid occlusion. The intrais chemic rectal temperature was either maintained at 36--37°C or allowed to fall passively to 28-32°C. Antago
nists and doses tested were I and 10 mg/kg of , 30 mg/kg of COS 19755 preis chemia, four 25 mg/kg doses of COS 19755 administered between 0.5 and 6.5 h postischemia, and 40 mg/kg of MDL 27, . All three NMDA re ceptor antagonists exhibited some degree of neuroprotec tive activity when the carotid occlusion was performed under normothermic conditions. Most of the treatments with antagonist markedly reduced striatal damage. CAl hippocampal and neocortical pyramidal cells were spared Transient global ischemia in humans preferen tially destroys neurons of the hippocampus, neo cortex, and striatum (Brierley and Graham, 1984) . A similar pattern of brain damage can be produced in experimental animals by reversible ligation of the carotid or carotid and vertebral arteries (Pulsinelli et al., 1982; Smith et al., 1984; Crain et al. , 1988) . The excessive activation of N-methyl-D-aspartate (NMDA) receptors by endogenous ligands, such as glutamate, has been suggested to play a key role in ischemia-related neurodegeneration (Choi and by only three of the treatments, however, and the extent of neuroprotection varied widely from case to case. Toxic doses of antagonist were required to protect CAl pyra midal cells from ischemic damage. Ischemic damage to hippocampal areas CA2-CA3a and CA4 appeared to be resistant to all of these treatments. Most CAl pyramidal cells that were protected from degeneration by an NMDA receptor antagonist were histologically abnormal. The neuroprotective effects of MK-80l and intraischemic hy pothermia appeared to be additive. MK-80l (10 mg/kg) consistently reduced the postischemic brain temperature, but only the magnitude of hypothermia produced soon after reperfusion correlated with its neuroprotective ac tion. These results suggest that NMDA receptor antago nists are relatively poor neuroprotective agents against a moderately severe ischemic insult. Key Words: Cerebral ischemia-Selective vulnerability-N-Methyl-D-as partate receptor antagonists-Excitatory aminoacids. Rothman, 1990) . Glutamate released during the pe riod of ischemia or during the immediate postisch ernie period opens NMDA receptor channels on brain neurons. Because these channels are highly permeable to Ca 2 + , the excessive activation of NMDA receptors leads to a toxic buildup of Ca 2+ within those neurons that cannot adequately buffer or eliminate it. If this hypothesis is correct, then NMDA receptor antagonists would be expected to reduce or prevent ischemic neuronal death. Tests of NMDA receptor antagonists in various animal mod els of cerebral ischemia have produced mixed re sults, however.
Initial studies of the uncompetitive antagonist MK-80l appeared to be very promising. Pretreat ment with as little as 0.1 mg/kg of MK-801 report edly protected CAl hippocampal pyramidal cells from transient forebrain ischemia in the gerbil (Gill et aI., 1987) . More importantly, MK-801 was said to prevent the death of CAl pyramidal cells when it was administered as long as 24 h after ischemia (Gill et aI., 1988) . Doses of 1-10 mg/kg could completely block the degenerative effects of transient ischemia upon this neuronal population. These results raised the hope that prompt administration of an NMDA receptor antagonist to victims of an ischemic insult, such as cardiac arrest or stroke, could reduce the subsequent neurological deficits. Most of the stud ies of MK-801 and other NMDA receptor antago nists that followed, however, yielded less dramatic neuroprotective effects (Boast et aI., 1988; Mar coux et a!. , 1988; Rod and Auer, 1989; Swan and Meldrum, 1990) and in some cases little or no ben eficial effect was obtained (Wieloch et a!. , 1988; Fleischer et a!. , 1989; Buchan and Pulsinelli, 1990; Lanier et a!., 1990) .
In general, NMDA receptor antagonists were most efficacious in studies where body temperature was neither monitored nor maintained during isch emia. The animals in these studies almost certainly became hypothermic during ischemia and hypother mia itself can protect neurons from ischemia induced degeneration (Busto et a!. , 1989) . Indeed, some investigators reported that MK-801 could re duce ischemic brain damage only when the antago nist lowered body temperature (Buchan and Pulsinelli, 1990; Corbett et a!. , 1990) , although oth ers have obtained equivalent neuronal sparing un der normothermic and hypothermic conditions (Ikonomidou et a!. , 1989; Gill and Woodruff, 1990; Swan and Meldrum, 1990) . We addressed this issue by studying the action of NMDA receptor antago nists at different intraischemic temperatures in the same series of animals and by investigating the ef fects of MK-801 on postischemic brain tempera ture.
Another important issue is that of regional differ ences in drug efficacy. Previous studies of NMDA receptor antagonists focused on the hippocampal CAl area. However, postanoxic encephalopathy in humans is characterized not only by CAl damage, but also by extensive neuronal degeneration in the neocortex and striatum. Lesions of the neocortex and striatum may cause functional impairments as serious as or more serious than hippocampal le sions. Only Wieloch et a!. (1988) examined brain regions outside the hippocampus, however, and they found no protective effect of MK-801 there. We therefore quantitated the neuroprotective ac tion of NMDA receptor antagonists in all three brain regions. Brief reports of this work have ap peared (Warner et a!. , 1989 (Warner et a!. , , 1990 .
METHODS

Bilateral carotid occlusions
Adult male Mongolian gerbils (60-110 g; Tumblebrook Farms, West Brookfield, MA, U.S.A.) were anesthetized with 2.5% halothane in air. Both common carotid arteries were exposed and then occluded with Schwartz clips for 5 min (Crain et aI., 1988) . The absence of carotid blood flow during the occlusion and the resumption of flow after removal of the clips were verified visually. Anesthesia was continued through the first 3 min of the occlusion; the total period of anesthesia was 20-25 min. During the in duction of anesthesia, surgery, and the entire period of carotid occlusion, the rectal temperature was either main tained at 36-37°C with a heating pad and incandescent lamp (normothermic) or allowed to fall passively (hypo thermic). The rectal temperature of the hypothermic an imals during the carotid occlusion ranged from 28 to 32°C, whether or not the animal had been treated with an NMDA receptor antagonist. In all cases, the rectal tem perature was monitored with a thermistor probe con nected to a telethermometer (model 43, Yellow Springs Instrument Co., Yellow Springs, OH, U.S.A.). The tele thermometer had a resolution of 0.2°C and the time con stant of the probe was 3.2 s.
Administration of drugs
The NMDA receptor antagonists tested were MK-801 (Huet tner and Bean, 1988) . MDL 27,266 is believed to act by binding to the same site as MK-801 and was claimed to possess superior neuroprotective activity against tran sient ischemia (Miller et aI., 1988) . CGS-J9755 competes with agonist for binding to the receptor (Lehmann et aI., 1988) . Antagonists were dissolved in 0.9% (w/v) NaCI to a final volume of 2.5 mllkg of body weight (MK-801) or 5 mllkg of body weight (CGS-19755 and MDL 27,266) . They were then administered intraperitoneally according to the following regimens: MK-801, 1 or 10 mg/kg given either 60 min before or 30 min after ischemia under either normothermic or hypothermic conditions; CGS-19755, 25 mg/kg given 30, 150, 270, and 390 min after ischemia un der normothermic conditions or 30 mg/kg given either at the same times after ischemia under hypothermic condi tions or 60 min before ischemia under normothermic or hypothermic conditions; and MDL 27,266, 40 mg/kg given either 60 min before or 30 min after ischemia under normothermic conditions. These dosing schedules were chosen because they had previously been reported as maximally neuroprotective in the gerbil (Gill et aI., 1987 (Gill et aI., , 1988 Boast et aI., 1988; Miller et aI., 1988) . Control an imals received an equal volume of 0.9% (w/v) NaCI ac cording to the same schedules. MK-801, CGS-19755, and MDL 27,266 
Histology
Four days after ischemia, the animal was deeply anes thetized with pentobarbital and perfused through the heart with phosphate-buffered 0.9% (w/v) NaCI for I min followed by 200 ml of 4% (w/v) paraformaldehyde in 0.1 M sodium phosphate buffer, pH 7.4. After I h, the brain was removed and placed in the fixative at 4°C for 3-10 days. The forebrain was then cut coronally into 40 f.lm thick frozen sections. Every 12th section rostral to the hippocampus and every 6th section through the hippo campus were impregnated with silver to visualize degen erating neurons and their processes (Nadler and Even son, \989) . Previous studies demonstrated that neurons become argyrophilic when they reach the stage of elec tron-dense degeneration, as defined with the electron mi croscope (Lund and Westrum, 1966; Heimer and Peters, 1968; Crain et aI., 1988) , and that the optimal time for demonstrating ischemic neuronal death in the gerbil is 3--4 days after the carotid occlusion (Crain et aI., 1988) . Ad jacent sections were stained with cresyl violet.
Neuronal degeneration in the hippocampal CAl area, the striatum, and the neocortex was quantitated by anal ysis of silver-impregnated brain sections cut at standard rostrocaudal levels defined by the atlas of Loskota et al. (1974) . For the striatum, the sections corresponded to levels 440 and 480 (0.7 and 0.3 mm rostral to the bregma, respectively). For area CAl , the sections corresponded to levels 650, 660, and 670 (1.4, 1.5, and 1.6 mm caudal to the bregma, respectively). For the neocortex, the sec tions corresponded to levels 440, 480, and 650. Drawings of each region on both sides of the brain were made with the aid of a camera lucida. The length or area of each structure of interest and of the silver-impregnated (dam aged) portion of each structure was determined with a digitizing tablet. Values of percent damage from the two or three sections were averaged to yield a single value for each region on each side of the brain. Only the values from the more severely damaged side were used.
Striatal degeneration was estimated by calculating the percentage of the total cross-sectional area of the striatum that was argyrophilic ( Fig. lA ). Both degenerating neu ronal somata and degenerating neuronal processes were present in this area. The degeneration of CAl hippocam pal pyramidal cells was estimated by calculating the per centage of the pyramidal cell body layer that contained 80% or more argyrophilic somata. This measurement was justified by the very short transition zone between por tions of the cell body layer with virtually complete neu ronal death and portions with virtually complete sparing when area CAl was only partially damaged ( Fig. 2B-D) . The degeneration of neocortical pyramidal cells was es timated by calculating the percentage of layer 3 (from the midline to the rhinal fissure) that contained argyrophilic pyramidal cells ( Fig. lA, B ). Because this measurement included motor and cingulate cortices, which suffered no ischemic damage, the maximum possible neocortical de generation was �80%. The medial portions of neocortex were included because it was often difficult to locate the border between the motor and somatosensory cortices.
RESULTS
Morbidity and mortality
Vehicle-injected ischemic controls recovered from halothane within a few minutes and assumed a hunched posture for about the next 0. 5 h. They then became noticeably hyperactive. The hyperactivity was not associated with electrographic seizures.
[Gerbils do not develop postischemic seizures un der our experimental conditions (Armstrong et aI., 1989) .] The doses of CGS-19755 and MDL 27,266 used were sufficient to produce flaccid paralysis in all animals. Reflexes (e. g. , corneal and toe pinch) re mained intact, however, consistent with dissocia tive anesthesia (Dundee, 1989) . Animals treated with I mg/kg of MK-801 appeared to be slightly hypoactive compared with the controls, but other wise behaved similarly to them.
Administration of NMDA receptor antagonists either before or after ischemia was associated with significant mortality, which appeared to result from respiratory insufficiency. Under normothermic conditions, 7 of 26 gerbils died after receiving 10 mg/kg of MK-801 and five of 25 died after receiving MDL 27,266. Under hypothermic conditions, two of 23 gerbils died after receiving 10 mg/kg of MK-801 and three of 17 died after receiving CGS-19755. In addition, the dose of CGS-19755 administered to gerbils after ischemia under normothermic condi tions had to be reduced from 30 to 25 mg/kg, be cause the higher dose was associated with exces sive mortality. Only two of 56 ischemic control an imals failed to survive for 4 days after surgery. This incidence of mortality in controls was similar to that of unoperated gerbils housed in our vivarium facil ity.
Histological analysis
Striatum
This brain region was readily protected from isch emic damage by NMDA receptor antagonists.
In control animals whose rectal temperature was maintained at 36-37°C (normothermic), 5 min of ischemia damaged an average of 30.9% of the stri atum ( Fig. lA , Table I ). Argyrophilic neurons and neuropil were observed primarily in the dorsolateral quadrant. When rectal temperature fell to 28-32°C before and during the carotid occlusion (hypother mic), striatal damage was reduced to <5% in 20 of 23 animals. In three animals, however, transient ischemia still damaged 18-24% of the striatum.
Most treatments with an NM DA receptor antag onist reduced striatal damage to a similar extent as intraischemic hypothermia (Fig. IB, C rostral two-thirds of the hippocampal formation ( Fig. 2A , Table 1 ) and also destroyed many neurons in areas CA2-CA3a and CA4. In only four of 31 animals was <90% of the CAl pyramidal cell body layer severely damaged ( Fig. 3) . When the carotid occlusion was performed under hypothermic condi tions, only about one-half as much of the CAl py ramidal cell body layer, on average, was severely damaged (Table 1 ). The extent of damage varied markedly, however (Fig. 3) . In 10 of the 23 animals, transient ischemia severely damaged < 10% of the layer, whereas it destroyed >90% of the layer in 9 animals. Thus, the neuroprotective effect of intra ischemic hypothermia in area CAl tended to be "all or nothing. " Intraischemic hypothermia little af fected the extent of ischemic damage to areas CA2-CA3a and CA4.
Under normothermic conditions, MK-801 and MDL 27,266, but not CGS-19755, could signifi cantly reduce the destruction of CAl pyramidal cells (Table I) . MK-801 at a dose of 10 mg/kg was about equally effective whether it was administered 60 min before or 30 min after ischemia. The extent of neuroprotection varied widely (Figs. 2B-D and 3) and only �37% of the pyramidal cell body layer, on average, was spared. In five of 19 animals, MK-801 protected >90% of the pyramidal cell body layer from damage, but in six animals it had no beneficial effect. At a dose of I mg/kg, MK-801 exhibited little neuroprotective activity (Table I) . However, in five of 16 animals (four given the drug before ischemia and I given the drug after ischemia), it reduced isch emic damage by 30% or more, compared with the mean damage in the controls. MDL 27,266 was clearly neuroprotective only when administered be fore ischemia (Table 1 ). When given at this time, it was about as efficacious as 10 mg/kg of MK-801. Like MK-801, its efficacy differed considerably from one animal to another. Of the 12 animals treated with MDL 27,266 before ischemia, five suf fered virtually no damage to area CAl, but CAl pyramidal cells were nearly all destroyed in four other cases.
It was impossible to demonstrate any statistically significant drug effect when the carotid occlusion was performed under hypothermic conditions, be cause ischemic damage to area CAl varied so greatly among control animals and because the ef fects of NMDA receptor antagonists were equally variable. However, CGS-19755 and 10 mg/kg of MK-801 reduced the mean extent of CAl damage by more than 40% (Table 1 ). The neuroprotective effects of intraischemic hypothermia and 10 mg/kg of MK-801 appeared to be additive (Fig. 3) . In more than one-half of the animals, I mg/kg of MK-801 
Area CAl Neocortex (layer 3) 30.9 ± 22.8 (7) 0.8 ± 1.6** (8) 0.0 ± 0.0** (II)
17.2 ± 21.6 (3) 7.2 ± 18.4** (6) 7.3 ± 14.7** (6) 4.7 ± 10.0** (5) 2.0 ± 6.9** (II) 14.6 ± 16.1 29.4 ± 37.0 (4) 2.1 ± 5.6 (6) 29.6 ± 42.3 (4) 11.4 ± 16.4 (4)
The percentages of the striatum, hippocampal area CA I, and layer 3 of the neocortex destroyed by transient forebrain ischemia were estimated as described in the Methods section. Values are means ± SD for N = number of animals. The number of animals in which the extent of damage was less than 10% of the mean control value under normothermic conditions is indicated in parentheses.
Experimental group differed from control at *p < 0.05 or **p < 0.01 (Dunnett's test) after two-way ANOV A (treatment x temper ature) yielded p < 0.01 for both variables. appeared to exacerbate ischemic damage when it was administered after ischemia.
Most CAl pyramidal cells that were protected from degeneration by intraischemic hypothermia, administration of an NMDA receptor antagonist, or both appeared histologically abnormal when im pregnated with silver (Fig. 4B ). The nucleoli of these cells were heavily stained and stood out prominently against the unusually pale cytoplasm. The same neurons appeared dark and irregularly shaped when stained with cresyl violet (see Kaplan et aI. , 1989) . In most animals, nearly every intact CA 1 pyramidal cell exhibited this appearance. When the extent of neuroprotection reached 90% or better, however, the CAl pyramidal cells assumed a normal or at least much less abnormal appearance (Fig. 4C ). NMDA receptor antagonists did not appear to re duce the extent of ischemic damage to area CA2-CA3a or area CA4. Neocortex NMDA receptor antagonists were only slightly more neuroprotective toward layer 3 neocortical pyramidal cells than toward CAl hippocampal py ramidal cells.
Transient ischemia under normothermic condi tions damaged an average of 41.8% of layer 3 (Table   1) , as well as portions of layer 6. Neocortical dam age was absent in 5 of the 31 control animals, how ever. When ischemic damage was present, it was largely confined to the somatosensory cortex ( lA, B). When the carotid occlusion was performed under hypothermic conditions, ischemic damage dropped to <10% in 17 of 23 animals. In only three animals did the damaged area exceed 25% of lay er 3.
MK-80l and MDL 27,266 significantly reduced the extent of neocortical damage when they were administered before ischemia (Fig. lC, Table I) .
Both 1 and 10 mg/kg of MK-80l abolished neocor tical damage in about one-half of the animals treated. The lower dose of MK-801 had no effect in three of 10 animals, but the higher dose always re duced the degeneration of layer three pyramidal cells by at least 50% compared with the average control animal. MDL 27,266 had an "all or nothing" effect in neocortex. In nine animals, it abolished neocortical damage, but it had no benefi cial effect in the other three animals. None of the NM DA receptor antagonists significantly reduced the extent of neocortical damage when the antago nist was administered after ischemia.
Intraischemic hypothermia and NMDA receptor antagonists spared layer 6 neocortical pyramidal cells to about the same extent as layer 3 pyramidal cells. The damage to layer 6 was not quantitated, however.
Postischemic brain temperature
Because postischemic temperature can be an im portant factor in the neuroprotective action of NM DA receptor antagonists, we investigated the possibility that variability among animals in their postischemic brain temperature accounted for their differing responses to these agents. For this pur pose, we implanted a separate set of gerbils with a removable thermocouple microprobe that permitted us to record brain temperature while the animals remained conscious and unrestrained (Neill et aI., 1990a) . The intraischemic brain temperature was maintained at 36-37°C and postischemic tempera ture was monitored, but not maintained.
All ischemic control animals (n = 10) developed a mild postischemic cerebral hyperthermia that nor mally outlasted the period of observation ( Fig. 5 ; see also Neill et aI. , 1990a) . In 17 animals treated with 10 mg/kg of MK-80l (9 preischemia and 8 postischemia), the brain temperature fell below the preanesthesia baseline and then oscillated between hypothermic and normothermic to hyperthermic. MK-801 reduced the mean postischemic brain tem perature during the first 4 h by about 2°C compared with the ischemic controls. However, when individ ual animals were compared, the neuroprotective ef ficacy of the drug in area CA 1 correlated poorly with the reduction in mean postischemic brain tem perature, the maximal reduction in postischemic brain temperature, or the total duration of postisch emic hypothermia. Neuroprotective efficacy did correlate, however, with the magnitude and dura tion of the first period of postischemic hypothermia (p < 0.001; Spearman rho rank correlation).
DISCUSSION
These results confirm findings of several other laboratories that NMDA receptor antagonists of both competitive and uncompetitive types can re duce ischemic brain damage in animals. In our hands, however, these agents proved to be less than ideal neuroprotective agents. Four disadvantageous findings were as follows: (a) Toxic doses of antag onist were required to protect any substantial num ber of CAl hippocampal pyramidal cells. (b) Neu roprotective activity varied considerably from one animal to another and total protection against tran sient ischemia was never achieved. (c) NM DA re ceptor antagonists appeared to be virtually ineffec tive in some brain regions, such as hippocampal areas CA2-CA3a and CA4. (d) CAl pyramidal cells that were protected from degeneration appeared histologically abnormal, except in those few cases where the antagonist was maximally neuroprotec tive.
Potency and efficacy of NMDA receptor antagonists in area CAl
The potency of MK-801 and the efficacy of all three NMDA receptor antagonists in limiting isch emic brain damage were lower in the present study than in most previous studies of global ischemia in rodents. For example, other investigators have re ported that 1 mg/kg of MK -801 protects most gerbil CA 1 hippocampal pyramidal cells from 5 min of ischemia (Gill et aI., 1987 (Gill et aI., , 1988 . In our studies, however, this dose of MK-801 had only weak neu roprotective activity, at best, in area CAl. Further more, allowing body temperature to fall during isch emia failed to elicit a more robust neuroprotective action.
In contrast to the relatively weak neuroprotective effects of NMDA receptor antagonists in vivo, the competitive antagonist CPP, i.e., 3-[(±)-2-carboxy piperazin-4-yl]-propyl-l-phosphonic acid, proved highly effective in preventing electrophysiological deterioration in the CAl area of hippocampal slices prepared from gerbils that had been made ischemic 20-30 min earlier (Urban et aI., 1990) . One possible explanation for this discrepancy is that antagonist was present at a relatively higher concentration or for a longer period of time in vitro than in vivo. The antagonists may not have reached extracellular con centrations in vivo equivalent to effective concen trations of CPP in vitro (2-10 f1M). However, the doses administered in vivo were sufficient to pro duce flaccidity for several hours, often to the point of respiratory depression. They could not have been increased without unacceptable mortality. An other possible explanation is that preparing the hip pocampal slice somehow ameliorates the effects of ischemia, perhaps by partially deafferenting area CA 1. Alternatively, there may be at least one etio logical factor in ischemia-induced degeneration that does not require NMDA receptor activation. This second factor is eliminated by preparing hippocam pal slices and could involve an ischemia-induced systemic change in the animal or a deleterious change in the extracellular milieu of the brain.
Variable effects of NMDA receptor antagonists in models of cerebral ischemia
Several explanations may be considered for the variable neuroprotective effects of NMDA receptor antagonists in different laboratories. One possibility is that NM DA receptor antagonists are inherently more potent or efficacious in some species than in others. A number of findings suggest that this is unlikely. For example, NMDA receptor antagonists have been reported by different groups either to attenuate (Rod and Auer, 1989; Swan and Meldrum, 1990) or not to affect (Wieloch et aI., 1988) brain damage in the rat two-vessel occlusion model of global ischemia. The marked difference between our results with MK-801 in the gerbil and those of Gill and co-workers (Gill et aI., 1987 (Gill et aI., , 1988 Gill and Woodruff, 1990 ) reinforces this point.
As stated earlier, body temperature may be a crit ical variable in the neuroprotective action of NM DA receptor antagonists, particularly with re spect to neuroprotection by MK-801. There are in deed similarities between the neuroprotective ef fects of NMDA receptor antagonists and intra ischemic hypothermia. In the present study, both variably reduced ischemic damage in area CAl but failed to protect neurons in other hippocampal re gions. Both preferentially reduced ischemic damage in the striatum and neocortex, compared with area CAL In addition, CAl pyramidal cells spared from ischemic damage by either an NMDA receptor an-tagonist or intraischemic hypothermia appeared his tologically abnormal unless a maximal neuroprotec tive effect had been achieved. Furthermore, we found that 10 mg/kg of MK-801 reduces the post ischemic brain temperature in our animals by �2°C, when temperature values were averaged over the first 4 h after ischemia. In some studies, prevention of this MK-80l-induced postischemic hypothermia reversed the neuroprotective action of the drug (al though only rectal, not brain, temperature was mea sured) (Buchan and Pulsinelli, 1990; Corbett et aI. , 1990) . These observations suggest that NMDA re ceptor antagonists and intraischemic hypothermia work through a common mechanism, at least at some level.
Nevertheless, it seems unlikely that differences in neuroprotection by NMDA receptor antagonists can be attributed simply to temperature differences. A number of reports have demonstrated at least some neuroprotective effect of NM DA receptor an tagonists when intraischemic and/or postischemic hypothermia was prevented (Ikonomidou et aI., 1989; Olney et aI. , 1980a; Gill and Woodruff, 1990; Swan and Meldrum, 1990) . The present study sug gests, in fact, that the neuroprotective effects of MK-801 and intraischemic hypothermia are addi tive, in agreement with Ikonomidou et al. (1989) . Furthermore, our studies of brain temperature indi cate that variability among animals in the neuropro tective effect of MK-801 cannot be explained sim ply by differences in the overall magnitude or dura tion of postischemic hypothermia.
The most likely explanation for the relatively poor performance of NM DA receptor antagonists as neuroprotective agents in the present study is that the ischemic insult was in some way more se vere than it was in studies that demonstrated greater potency or efficacy of these antagonists. Previous studies of NM DA receptor antagonists in cerebral ischemia have not reported striatal or neo cortical damage in the control animals. In part, this may reflect the difficulty of detecting such damage with conventional histological staining techniques after a survival time of 4 days or more. More likely, however, the lack of observable ischemic damage outside the hippocampus can be explained largely by a less severe ischemic insult than we adminis tered. Possibly, their animals experienced a lower intraischemic or postischemic brain temperature than ours, even when rectal temperature was the same. The studies of Ginsberg, Globus, and their colleagues (Busto et aI., 1987 (Busto et aI., , 1989 have clearly shown that the neuropathological outcome of tran sient ischemia depends more importantly on brain temperature than on rectal temperature. Moreover, J Cereb Blood Flow Me/ab, Vol. II, No. 4, 1991 rectal temperature does not accurately reflect brain temperature under all experimental conditions (Busto et aI. , 1987; Neill et aI. , 1990a) . It is uncer tain whether brain temperatures are equivalent in studies that report similar rectal temperatures, be cause the two measures can be differentially af fected by the positioning of heating pads, blankets, or lamps. Another possibility is that ischemia pro voked a greater release of glucocorticoids in our animals (Sapolsky and Pulsinelli, 1985) . As sug gested by Wieloch et al. (1988) , NM DA receptor antagonists would probably be less efficacious against a relatively severe ischemic insult than against a threshold insult.
Regional differences in neuroprotective activity
NM DA receptor antagonists most readily pro tected striatal neurons from ischemic damage, pro tected neocortical and CA 1 pyramidal cells less well, and little affected the degeneration of hippo campal neurons in areas CA2-CA3a and CA4. This regionally selective neuroprotective effect is not specific to NMDA receptor antagonists. Hypother mia protects brain neurons from transient ischemia in the same order of preference (M inimisawa et aI. , 1990; Neill et aI. , 1990b) . In addition, prior lesion of an excitatory hippocampal pathway spares some CA 1 pyramidal cells from a subsequent ischemic insult, but fails to protect other hippocampal neu rons (Kaplan et aI. , 1989) . Thus, all treatments that reduce brain damage in our global ischemia model favor the same neuronal popUlations over others.
These regional preferences cannot easily be ex plained by differences in neuronal size, innervation pattern, rate of ischemia-induced degeneration, or NMDA receptor density. The most plausible hy pothesis is that vulnerable brain neurons have dif ferent thresholds for ischemic cell damage or cell death. NM DA receptor antagonists, hypothermia, and removal of excitatory innervation may enhance the ability of these neurons to withstand ischemia by moving the neurotoxic conditions farther from threshold. In this view, NMDA receptors, temper ature, and synaptic excitation are three of many factors that determine the level of ischemic insult. Removing any of these factors can spare neuronal populations to varying degrees. CA4 and CA2-CA3a hippocampal neurons may have such a low threshold for ischemic damage that it is virtually impossible to prevent their degeneration by remov ing any single contributory factor.
Histological appearance of spared neurons
The histological appearance of CAl pyramidal cells spared from ischemic damage by treatment with an NMDA receptor antagonist raises concern about the functional capabilities of these neurons. Except in cases where the antagonist prevented nearly all ischemic damage in area CA I, the remain ing pyramidal cells appeared abnormal when im pregnated with silver or stained with cresyl violet. CAl pyramidal cells with prominently argyrophilic nucleoli and very pale cytoplasm were also ob served after silver impregnation when ischemic damage was reduced by intraischemic hypothermia or prior lesion of an excitatory hippocampal path way (Kaplan et aI. , 1989) . In the latter case, pyra midal cells with this appearance persisted intact for at least 4 weeks after ischemia. Argyrophilic nucle olus/pale cytoplasm normally characterizes a tran sition stage in the ischemia-induced degeneration of these neurons, typical of the period that precedes overt degeneration (1-2 days after ischemia) (Crain et aI., 1988) . Electrophysiological studies demon strated that CAl pyramidal cells developed this ab normal histological appearance after they had be come largely unresponsive to orthodromic or anti dromic stimulation (Urban et aI. , 1989) . Our observations thus suggest that many neurons pro tected from ischemic damage by an NMDA recep tor antagonist, although viable, are not electrophys iologically competent.
In contrast to our assessment of histological ma terial, Gill and Kemp (1989) reported that CAl py ramidal cells protected by MK-801 were function ally normal as assessed by electrophysiological cri teria. However, MK-801 had fully protected area CAl from ischemic damage in their study. Judging from our work, the pyramidal cells studied by Gill and Kemp were probably histologically, as well as electrophysiologically, normal. It remains to be de termined whether these neurons retain normal elec trophysiological function under more typical condi tions, i.e. , conditions in which <90% of CAl pyra midal cells are spared and the residual pyramidal cells appear histologically abnormal.
NMDA receptor antagonists as potential therapeutic agents
Transient global ischemia in experimental ani mals is principally relevant to clinical states that produce similar brain damage, such as cardiac ar rest and near drowning. Since NMDA receptor an tagonists can reduce ischemic brain damage in ani mals when administered after the period of ischemia and since it is possible to treat victims of cardiac arrest within a short time after their attack, NMDA receptor antagonists have been recommended for clinical trial (Schwarcz and Meldrum, 1985; Albers et aI., 1989) . Our results suggest that the clinical efficacy of these agents may be quite limited, at least when given by themselves. NMDA receptor antagonists can markedly reduce neuronal degener ation in experimental animals after a relatively mild ischemic insult, and they are especially effective against focal ischemia (Ozyurt et aI. , 1988; Park et aI. , 1988; Roman et aI. , 1989; Steinberg et aI., 1989) and during development (McDonald et aI. , 1987; Ol ney et aI. , 1989a ). However, when tested in adult animals that received a global ischemic insult se vere enough to damage the striatum and neocortex, they proved disappointing. Ischemic damage of this severity is common in humans (Brierley and Gra ham, 1984) . Furthermore, the phencyclidine-like antagonists, such as MK-801, may themselves be neurotoxic (Olney et aI. , 1989b) . NMDA receptor antagonists may therefore be most useful as part of a regimen consisting of several treatments whose neuroprotective effects should be at least additive. Such a regimen might include hypothermia and a combination of NMDA receptor antagonist with a dissimilar type of neuroprotective agent, such as a free radical scavenger (Werns and Lucchesi, 1990) .
